{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:08:10Z","timestamp":1781917690953,"version":"3.54.5"},"reference-count":19,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Background:<\/jats:title>\n<jats:p>Studies comparing head-to-head treatment modalities for anogenital warts are lacking.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Aim:<\/jats:title>\n<jats:p>We sought to compare a short, 8-week course of imiquimod 5% cream to versus the standard 4 week course of podophyllotoxin in the treatment of anogenital warts and to assess factors that may affect response to treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Methods:<\/jats:title>\n<jats:p>This was a retrospective cohort study. We reviewed medical files of otherwise healthy patients with a first episode of anogenital warts who were treated with either a short, 8-week course of imiquimod or the standard 4-week course of podophyllotoxin. Inverse probability of treatment weighted (IPTW). Logistic regression was employed to evaluate factors that may affect response to therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st4\">\n<jats:title>Results:<\/jats:title>\n<jats:p>The study included 347 patients. In patients with lesions on dry, keratinized anatomical sites, the complete clearance rates were 7.6% for imiquimod and 27.9% for podophyllotoxin (<jats:italic>P<\/jats:italic> &lt; 0.001). In patients with lesions on moist, partially keratinized sites, no difference between the treatments was revealed. Significant predictors of &gt; 50% reduction in wart area were location of lesions [odds ratio (OR) (95% confidence interval (CI)): 3.6 (1.84\u20137.08), <jats:italic>P<\/jats:italic> = 0.0002] for \u201cpartially keratinized\u201d versus \u201ckeratinized\u201d sites and treatment used [OR (95% CI): 1.79 (1.08\u20132.97), <jats:italic>P<\/jats:italic> = 0.024] for podophyllotoxin versus imiquimod.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st5\">\n<jats:title>Limitations:<\/jats:title>\n<jats:p>The retrospective design of the study was a limitation that we mitigated against with the use of IPTW logistic regression.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st6\">\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>A standard 4 week course of Podophyllotoxin was more effective than an 8-week course of imiquimod only for lesions on keratinized sites. Treatment with podophyllotoxin and location of lesions on partially keratinized sites were independent predictors of &gt;50% reduction in wart area.<\/jats:p>\n<\/jats:sec>","DOI":"10.4103\/ijdvl.ijdvl_148_19","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T12:36:07Z","timestamp":1571834167000},"page":"666-670","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A short, 8-week course of imiquimod 5% cream versus podophyllotoxin in the treatment of anogenital warts: A retrospective comparative cohort study"],"prefix":"10.25259","volume":"87","author":[{"given":"Electra","family":"Nicolaidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Kanelleas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nikolakopoulos","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Germany,"},{"name":"Department of Statistics, CBS Laboratory, Athens University of Economics and Business, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bezrodnii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Nearchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gerodimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Papadopoulou-Skordou","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Paparizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rigopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2334-13-39","article-title":"Systematic review of the incidence and prevalence of genital warts","volume":"13","author":"Patel","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1111\/j.1468-3083.2012.04493.x","article-title":"2012 European guideline for the management of anogenital warts","volume":"27","author":"Lacey","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-3","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000095039","article-title":"Meta-analysis of 5% imiquimod and 0.5% podophyllotoxin in the treatment of condylomata acuminata","volume":"213","author":"Yan","year":"2006","journal-title":"Dermatology"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/OLQ.0b013e3181f68ebb","article-title":"Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts","volume":"38","author":"Komericki","year":"2011","journal-title":"Sex Transm Dis"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1258\/095646203321264827","article-title":"The cost-effectiveness of patient-applied treatments for anogenital warts","volume":"14","author":"Williams","year":"2003","journal-title":"Int J STD AIDS"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20240","article-title":"Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: Systematic review and economic evaluation","volume":"20","author":"Thurgar","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0190-9622(98)70243-9","article-title":"Treatment of genital warts with an immune-response modifier (imiquimod)","volume":"38","author":"Beutner","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1258\/095646206777689161","article-title":"An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women","volume":"17","author":"Garland","year":"2006","journal-title":"Int J STD AIDS"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1128\/AAC.42.4.789","article-title":"Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts","volume":"42","author":"Beutner","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/archderm.134.1.25","article-title":"Human papilloma virus","volume":"134","author":"Edwards","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/00007435-200104000-00007","article-title":"Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day","volume":"28","author":"Fife","year":"2001","journal-title":"Sex Transm Dis"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-13","first-page":"642","article-title":"Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts","volume":"16","author":"Sch\u00f6fer","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1346-8138.2004.tb00568.x","article-title":"Topical imiquimod 5% cream in external anogenital warts: A randomized, double-blind, placebo-controlled study","volume":"31","author":"Arican","year":"2004","journal-title":"J Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-15","first-page":"263","article-title":"Podophyllotoxin 0.5% v podophyllin 20% to treat penile warts","volume":"64","author":"Edwards","year":"1988","journal-title":"Genitourin Med"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(89)92282-4","article-title":"Patient-applied podofilox for treatment of genital warts","volume":"1","author":"Beutner","year":"1989","journal-title":"Lancet"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0002-9343(90)90424-C","article-title":"Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts","volume":"88","author":"Kirby","year":"1990","journal-title":"Am J Med"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/sti.71.6.387","article-title":"Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution","volume":"71","author":"Strand","year":"1995","journal-title":"Genitourin Med"},{"key":"10.4103\/ijdvl.IJDVL_148_19\/ref-19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/sti.79.4.270","article-title":"Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts","volume":"79","author":"Lacey","year":"2003","journal-title":"Sex Transm Infect"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/a-short-8-week-course-of-imiquimod-5-cream-versus-podophyllotoxin-in-the-treatment-of-anogenital-warts-a-retrospective-comparative-cohort-study\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/a-short-8-week-course-of-imiquimod-5-cream-versus-podophyllotoxin-in-the-treatment-of-anogenital-warts-a-retrospective-comparative-cohort-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T18:23:11Z","timestamp":1629310991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/a-short-8-week-course-of-imiquimod-5-cream-versus-podophyllotoxin-in-the-treatment-of-anogenital-warts-a-retrospective-comparative-cohort-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":19,"alternative-id":["10.4103\/ijdvl.IJDVL_148_19"],"URL":"https:\/\/doi.org\/10.4103\/ijdvl.ijdvl_148_19","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"article-number":"666"}}